WO1999019488A8 - Novel human egf receptors and use thereof - Google Patents

Novel human egf receptors and use thereof

Info

Publication number
WO1999019488A8
WO1999019488A8 PCT/US1998/021828 US9821828W WO9919488A8 WO 1999019488 A8 WO1999019488 A8 WO 1999019488A8 US 9821828 W US9821828 W US 9821828W WO 9919488 A8 WO9919488 A8 WO 9919488A8
Authority
WO
WIPO (PCT)
Prior art keywords
novel human
human egf
egf receptors
growth factor
present
Prior art date
Application number
PCT/US1998/021828
Other languages
French (fr)
Other versions
WO1999019488A9 (en
WO1999019488A1 (en
Inventor
Michael Klagsbrun
Klaus Elenius
Gabriel Corfas
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Priority to AU98053/98A priority Critical patent/AU9805398A/en
Publication of WO1999019488A1 publication Critical patent/WO1999019488A1/en
Publication of WO1999019488A9 publication Critical patent/WO1999019488A9/en
Publication of WO1999019488A8 publication Critical patent/WO1999019488A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates generally to epidermal growth factor receptors. More specifically, the present invention relates to novel isoforms of human epidermal growth factor receptor, particularly HER4/ErbB4, and uses thereof.
PCT/US1998/021828 1997-10-15 1998-10-15 Novel human egf receptors and use thereof WO1999019488A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU98053/98A AU9805398A (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6237397P 1997-10-15 1997-10-15
US60/062,373 1997-10-15

Publications (3)

Publication Number Publication Date
WO1999019488A1 WO1999019488A1 (en) 1999-04-22
WO1999019488A9 WO1999019488A9 (en) 1999-06-03
WO1999019488A8 true WO1999019488A8 (en) 1999-10-14

Family

ID=22042059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/021828 WO1999019488A1 (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Country Status (2)

Country Link
AU (1) AU9805398A (en)
WO (1) WO1999019488A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216331A (en) * 2008-10-17 2011-10-12 霍夫曼-拉罗奇有限公司 Treatment method

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000244A2 (en) 1999-06-25 2001-01-04 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
DE10084743T1 (en) 1999-06-25 2002-08-14 Genentech Inc Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
TR200200472T2 (en) 1999-08-27 2002-06-21 Genentech, Inc. Dosages for treatment with anti-Erb B2 antibodies
KR20020093029A (en) 2000-04-11 2002-12-12 제넨테크, 인크. Multivalent Antibodies And Uses Therefor
PL217410B1 (en) 2000-05-19 2014-07-31 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
US6255111B1 (en) 2000-07-31 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of Her-4 expression
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
CA2490758C (en) 2002-07-15 2014-09-23 Genentech, Inc. Dosage form of recombinant humanized monoclonal antibody 2c4
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
CN102580084B (en) 2005-01-21 2016-11-23 健泰科生物技术公司 The fixed dosage of HER antibody is administered
SI1850874T1 (en) 2005-02-23 2014-01-31 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
AU2008223069B2 (en) 2007-03-02 2012-12-13 F. Hoffmann-La Roche Ag Predicting response to a HER dimerisation inhibitor based on low HER3 expression
EP2171090B1 (en) 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
BRPI0916092A2 (en) 2008-11-25 2015-11-17 Genentech Inc "specific anti-her4 antibody isoforms"
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
RU2016105962A (en) 2009-12-04 2018-11-23 Дженентек, Инк. MULTI-SPECIFIC ANTIBODIES, ANTIBODIES ANALOGUES, COMPOSITIONS AND METHODS
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
SI2606070T1 (en) 2010-08-20 2017-04-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
BR112014004762A2 (en) 2011-08-31 2018-06-19 Genentech Inc methods of determining tumor cell growth sensitivity to inhibition by an egfr kinase inhibitor, identifying a cancer patient who is likely to benefit from treatment with an efgr inhibitor, treating cancer in a patient, selecting a therapy for a cancer patient and determining erbb2 gene overexpression in a cell
SG11201402510TA (en) 2011-11-30 2014-06-27 Genentech Inc Erbb3 mutations in cancer
ES2758433T3 (en) 2011-12-05 2020-05-05 Novartis Ag Antibodies to epidermal growth factor receptor 3 (HER3)
JP2015514710A (en) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
WO2015148531A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
JP6755235B2 (en) 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Inhibition of HER3 in low-grade serous cancer
KR20190140952A (en) 2017-04-24 2019-12-20 제넨테크, 인크. ERBB2 / HER2 mutations in transmembrane and proximal membrane domains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3963295A (en) * 1994-10-14 1996-05-06 Bristol-Myers Squibb Company Her4 human receptor tyrosine kinase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216331A (en) * 2008-10-17 2011-10-12 霍夫曼-拉罗奇有限公司 Treatment method

Also Published As

Publication number Publication date
AU9805398A (en) 1999-05-03
WO1999019488A9 (en) 1999-06-03
WO1999019488A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
WO1999019488A8 (en) Novel human egf receptors and use thereof
AU1746600A (en) Reduction, elimination, or stimulation of hair growth
IN1998DE01360A (en)
AU7483398A (en) Skin care compositions and method of improving skin appearance
ZA9710098B (en) Halogenopyrimidines.
AU6208198A (en) Novel modifications of 2-amino-4-(4-flourobenzylamino)-1- ethoxycarbonylaminobenzene, and processes for their preparation
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
ZA9711121B (en) Reduction of hair growth.
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
AU9319798A (en) Reduction of hair growth
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
ZA9711328B (en) Reduction of hair growth.
AU2002332923A1 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
EP1510579A3 (en) Use of heregulin as an epithelial cell growth factor
AU5390396A (en) Extracellular/epidermal growth factor hcaba58x
AU1903799A (en) Compositions and methods for modulating the activity of fibroblast growth factor
BG101787A (en) Aprotinine options having improved properties
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
AU6045499A (en) Antisense modulation of crel expression
AU5486500A (en) Antisense modulation of jun n-terminal kinase kinase-2 expression
WO2002060382A3 (en) Novel compounds and uses thereof
AU2436095A (en) Cloning, expression, and uses of human lactoferrin
AU5549296A (en) Extracellular/epidermal growth factor-like protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA